Submitted by Anonymous (not verified) on 6 May 2025 - 16:12
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 6, Status: Authorised